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We examined the potential of quantitative epidermal growth factor receptor (EGFR, synonym: c-erbB-1) and c-erbB-2 (synonym:
HER2/neu) mRNA expression to predict minor or major histopathologic response to neoadjuvant radiochemotherapy (cis-platinum,
5-FU, 36Gy), followed by radical surgical resection, in patients with oesophageal cancer. Tissue samples were collected by
endoscopic biopsy prior to treatment. RNA was isolated from biopsies and quantitative real-time reverse transcriptase–polymerase
chain reaction assays were performed to determine c-erbB-1 and c-erbB-2 mRNA expression. Relative expression (tumour/paired
normal tissue ratio standardised for b-actin) was calculated for EGFR and c-erbB-2 mRNA. Expression levels were correlated with the
objective histopathologic response in resected specimens. Histomorphologic regression was defined as major response when
resected specimens contained less than 10% of residual vital tumour cells, or in case a pathologically complete response was achieved.
Expression of c-erbB-1 mRNA was not associated with the degree of histomorphological response. In contrast, the relative
expression levels of c-erbB-2 mRNA 41 were not associated with major histopathologic responses (sensitivity 41.6%, specificity
100%), and 10 out of 36 (28%) patients could be unequivocally identified, whose tumours did not respond well to the delivered
neoadjuvant radiochemotherapy (Po0.01). Quantitative expression levels of c-erbB-2, but not c-erbB-1 mRNA, in pretreatment
biopsies appear to predict minor histopathologic response to our neoadjuvant radiochemotherapy protocol. This test could be used
to prevent expensive, noneffective and potentially harmful therapies in approximately one-fourth of our patients, and leads to a more
individualised type of combined modality treatment.
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Patients with locally advanced oesophageal cancers have a poor
prognosis when treated exclusively by surgical resection. There-
fore, many investigators apply neoadjuvant treatment strategies in
an effort to improve survival (Sherman et al, 2002). Results from
phase III randomised trials are encouraging; however, they
revealed that only patients with major histopathologic response
will eventually benefit from treatment (Walsh et al, 1996; Urba
et al, 2001; MRC Esophageal Study Group, 2002). In addition, these
therapies are expensive and associated with increased therapy-
induced complication rates (Kelsen, 2000). Predictive molecular
markers indicating response or nonresponse to neoadjuvant
treatment would be extremely helpful in selecting patients for
future treatment protocols.
Epidermal growth factor receptor (EGFR, synonym: c-erbB-1)
and c-erbB-2 (synonym: HER2/neu) are members of the type I
growth factor receptor gene family (Gullick, 2001). The c-erbB-1
gene encodes a 170kDa membrane protein. Under physiologic
conditions, binding of epidermal growth factor (EGF) or transform-
ing growth factor-a (TGF-a) leads to receptor kinase activity, and
subsequently a complex cascade of events that can induce cellular
proliferation (Harris et al, 2003; Jorissen et al, 2003). The c-erbB-2
gene encodes a 185kDa transmembrane glycoprotein (p185) with
tyrosine kinase activity (Wang and Hung, 2001).
Overexpression of c-erbB-1 or c-erbB-2 mRNA and/or protein
has been implicated in the pathogenesis of various solid tumours
including breast, ovarian, lung and oesophageal cancers; however,
association with prognosis varied substantially between studies
and tumour entities (Meden et al, 1994; Singleton et al, 1994;
Schneider et al, 2000; Brabender et al, 2001; Esteva et al, 2002; Lau
et al, 2002).
In tumour cell lines, the sensitivity to several chemotherapeutic
agents (Kroning et al, 1995; Dixit et al, 1997; Nouri et al, 2000) and
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lradiotherapy (Kwok and Sutherland, 1989; Bonner et al, 2002) was
significantly modified by EGF or EGFR expression levels. In
addition, there is evidence that blocking EGFR could further
increase chemo- and radiosensitivity of tumour cells expressing
high receptor levels in vitro and in vivo (Anderson and Jankowski,
2003; Gee and Nicholson, 2003).
Several studies demonstrated an association between
the expression of c-erbB-2 and the response to adjuvant
chemotherapy in breast cancer (Allred et al, 1992; Muss
et al, 1994; Miles et al, 1999; Menard et al, 2001). These results,
however, are challenged by negative data in other adjuvant
or neoadjuvant trials (Rozan et al, 1998; Wang et al, 2002;
Zhang et al, 2003). Trial results might also depend on the
chemotherapeutic agents used (Muss et al, 1994; Wang et al, 2002).
In addition, anti-p185-specific antibodies enhanced cis-platin
(CDDP) sensitivity (Hancock et al, 1991; Pietras et al, 1994) and
radiosensitivity (Pietras et al, 1999) in vitro, and promising results
have already been reported in a clinical phase II trial using a
combination of recombinant anti-p185-HER2/neu monoclonal
antibody plus CDDP in refractory metastatic breast cancer
(Pegram et al, 1998).
The purpose of this prospective study was to investigate the
potential of quantitative c-erbB-1 and c-erbB-2 mRNA expression
in pretreatment biopsies to predict a minor or major histopatho-
logic response to neoadjuvant therapy with CDDP, 5-fluorouracil
(5-FU) and simultaneous radiation (36Gy), followed by surgical
resection in oesophageal cancers.
PATIENTS AND METHODS
Study population, demographic data and neoadjuvant
therapy
All patients were recruited from an ongoing clinical trial on
neoadjuvant radiochemotherapy for oesophageal cancer. None of
the patients had prior radio- and/or chemotherapy.
In all, 36 consecutive patients (median age: 59.6 years,
range 29.5–72.7; gender: 29 men, seven women) with locally
advanced, resectable oesophageal cancers (cT2-4, Nx, M0, UICC/
AJCC TNM Classification) in good general health condition
(ECOG performance status 0–1) and normal to moderate risk
factors for oesophageal surgery (Bollschweiler et al, 2000)
were offered standardised neoadjuvant radiochemotherapy. Clin-
ical staging was based on barium swallow, endoscopic ultrasound
and CT of the chest and abdomen. Diagnostic laparoscopy
was performed in all patients with adenocarcinomas to exclude
peritoneal carcinomatosis. CDDP (20mgm
2day
 1) was adminis-
tered as short-term infusion on days 1–5 and 5-fluorouracil
(1000mgm
2day
 1) as continuous infusion over 24h on days 1–5.
Radiation therapy was administered by linear accelerators
with 10–15MV photons. Radiation therapy was simulated to
encompass the tumour volume with 5cm cephalo-caudad-margins
and 2cm radial margins, and treatment ports were designed
to include enlarged regional nodes based on CT evaluation
and endoscopic ultrasound. Radiation was delivered in daily
fractions of 1.8Gy (days 1–5, 8–12, 15–19 and 22–26) to a
total dose of 36Gy using a multiple-field technique. Surgical
resection was performed 4–5 weeks following completion
of chemoradiation after clinical restaging using the same
procedures as for staging, except for laparoscopy. Standardised
transthoracic en bloc oesophagectomy with two-field lymphade-
nectomy and reconstruction by gastric tube interposition with
either left cervical or high intrathoracic anastomosis was
performed in all patients (Schroeder et al, 2002). Clinical data of
the patients are summarised in Table 1.
Informed consent was obtained from each patient and the
scientific protocol was approved by the local ethic committee.
Histomorphologic grading of tumour regression
Since clinical response evaluation after neoadjuvant therapy for
oesophageal cancer was known to be highly inaccurate (Adelstein
et al, 1997), objective histopathologic response analysis was
applied using morphologic criteria described by Junker et al
(1997).
The resected specimens were fixed in 10% formaldehyde, en bloc
embedded in paraffin and sectioned into 5-mm slices which were
stained with haematoxylin and eosin. These sections were used for
both histopathologic staging according to the TNM classification
system (UICC 5th edition, 1997) and histomorphologic evaluation
of the effect of radiochemotherapy. The degree of histomorpho-
logic regression was classified into four categories: grade I: 450%
vital residual tumour cells (VRTC), grade II: 10–50% VRTC, grade
III: nearly complete response (NCR) with o10% VRTC and grade
IV: complete response (pCR, ypT0). This analysis was performed
by two independent staff pathologists who were blinded for all
other clinical data (SEB and HPD), and there was no interobserver
variation in response classification.
Regression grades III and IV were considered as major
histomorphologic response (MaHR) compared to grades I and II
constituting minor histopathologic response (MiHR).
Tissue acquisition and RNA isolation
Tissue samples from oesophageal cancers and corresponding
normal tissues were collected by endoscopic biopsy prior to
starting neoadjuvant treatment. Samples were snap-frozen in
liquid nitrogen and stored at  801C until further processing.
Samples were carefully chosen after control staining with
haematoxylin and eosin of individual biopsies, and contained
450% tumour cells.
Total cellular RNA was isolated using Trizol reagent (Life
Technologies/GIBCO, Grand Island, NY, USA) and quantitated at
A260/280nm (Smart Spec; Biorad, Hercules, CA, USA).
Table 1 Clinical and histopathologic parameters (patients with tumour
resection: 36)
Parameter Subtype Number %
Histology Squamous 23 63.9
Adeno 13 36.1
ypT-category
a T0 2 5.6
T1 1 2.8
T2 7 19.4
T3 25 69.4
T4 1 2.8
ypN-category
b N0 15 41.7
N1 21 58.3
R-category
c R0 31 86.1
R1 5 13.9
R2 0 0
Grading G1 0 0
G2 12 33.3
G3 24 66.7
Regression grade
d I 15 41.7
II 9 25
III 10 27.8
IV 2 5.6
aHistopathologic tumour category after neoadjuvant therapy according to UICC
(Union Internationale Contre Le Cancer, 5th edition, 1997).
bHistopathologic lymph
node category after neoadjuvant therapy according to UICC (Union Internationale
Contre Le Cancer, 5th edition, 1997).
cResidual tumour category according to UICC
(Union Internationale Contre Le Cancer, 5th edition, 1997).
dGrade I: 450% vital
residual tumour cells (VRTC), grade II: 10–50% VRTC, grade III: nearly complete
response (NCR) with o10% VRTC and grade IV: complete response (pCR, ypT0).
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Total cellular RNA (0.5mg) was reverse-transcribed using an oligo
(dT)18 primer and Moloney murine leukaemia virus (MMLV)
reverse transcriptase (Clontech Lab, Palo Alto, USA), according to
the manufacturer’s recommendation. Placenta RNA from this kit
was used to prepare standard curves. An amount of 25ng of cDNA
was taken for real-time PCR using the Light Cycler System (Roche,
Mannheim, Germany). Amplification was monitored by SybrGreen
intercalation. For hot start LC-DNA, Master SYBR Green was
preincubated with TaqStartt antibody (Clontech Lab, Palo Alto,
USA), as suggested by the manufacturer. In addition, the 10ml
reaction volume contained 2mM MgCl2 and 1mM of each primer.
Primers used for PCR amplification were chosen to encompass
intron between exon sequences to identify false-positive DNA
amplification.
Three sets of published primers EGFR-F/EGFR-R (Pawlowski
et al, 2000), ERB-2/ERB-3 (Ninomiya et al, 1992) and P5/P6
(Tokuchi et al, 1999) were purchased (Eurogentec, Seraing,
Belgium) and used to amplify EGFR mRNA, c-erbB-2 mRNA and
b-actin mRNA, respectively. A 250bp amplification product was
obtained for c-erbB-1 mRNA, a 183bp product for c-erbB-2 and a
276bp product for b-actin mRNA. We used the expression of
b-actin mRNA to normalise the level of expression of EGFR and
c-erbB-2 mRNA. Thermal cycling conditions for EGFR were 30s at
951C for initial denaturation, followed by 35 cycles of 951C for 0s,
681C for 20s and 721C for 20s; for c-erbB-2, 30s at 951C for initial
denaturation, followed by 35 cycles of 951C for 0s, 641C for 20s
and 721C for 20s; and for b-actin, 30s at 951C, followed by 40
cycles of 951C for 0s, 631C for 20s and 721C for 20s. We used
serial dilutions of standard cDNA synthesised from human
placenta total cellular RNA (Clontech Lab Inc, Palo Alto, CA,
USA) for the quantification analysis. Triplicates of the clinical
samples and duplicates of standard cDNA dilutions were assayed
in each run. Product purity was controlled by melting point
analysis and PCR products were further analysed electrophoreti-
cally in 2% agarose gels using a Horizon 58 electrophoresis
chamber (GIBCO/BRL, Eggenstein, Germany) and visualised by
ethidium bromide staining.
Absolute mRNA expression levels were calculated as c-erbB-1 or
c-erbB-2/b-actin in tumour and normal tissue, respectively, and
relative mRNA expression levels (ratio tumour/normal) were
calculated as (c-erbB-1 or c-erbB-2/b-actin in tumour)/(c-erbB-1
or c-erbB-2/b-actin in paired normal tissue).
Statistical analysis
Gene expression levels were described using the median as point
estimator and the range of values. Cutoff values for discrimination
of mRNA expression levels and histopathologic response were
derived from receiver operating curve (ROC) data (area under the
curve and the 95% confidence interval) according to Metz et al
(1973).
Associations between dichotomised gene expression levels and
clinico-pathological parameters were evaluated using w
2-analysis
and Fisher’s exact test for significance (Software Package SPSS for
Windows, Version 11.0, Chicago, IL, USA).
P-values are given for two-sided testing and the level of
significance was set to Po0.05.
RESULTS
Distribution of c-erbB-1 and c-erbB-2 mRNA expression
levels
Quantitative expression levels of c-erbB-1 and c-erbB-2 mRNA
were evaluated in 36 patients in tumour and corresponding normal
tissues from pretreatment biopsies. The Median absolute c-erbB-1
mRNA expression levels standardised for b-actin were 0.115 (min.
0.001, max. 2) in tumour and 0.103 (min. 0.003, max. 1.467) in the
corresponding normal tissue. The calculated median relative
expression level (T/N ratio) was 1.082 (min. 0.008, max. 27.148).
For c-erbB-2 mRNA expression, median absolute levels standar-
dised for b-actin were 0.401 (min. 0.002, max. 7) in tumour and
0.634 (min. 0.11, max. 62.091) in paired normal tissues. The
calculated median relative c-erbB-2 mRNA expression level (T/N
ratio) was 0.595 (min. 0.007, max. 7.873).
Histopathologic response to radiochemotherapy and
c-erbB-1 mRNA expression
Relative overexpression of c-erbB-1 mRNA with a T/N ratio 41.0
was detected in 20 out of 36 (55.6%) tumours and normal to low
relative expression with a T/N ratio p1.0 in 16 out of 36 (44.4%),
respectively. The association of dichotomised relative expression
levels (T/N ratiop1.0 vs 41) and histopathologic response grades
is shown in Table 2. This association is statistically not significant
(P¼1), with a low sensitivity (54.1%) and specificity (65%) to
predict minor histopathologic response.
A cutoff value for relative c-erbB-1 mRNA expression and
discrimination of minor histopathologic response was derived
from ROC curves for a relative c-erbB-1 mRNA expression level
of 3.318 (area under the curve: 0.476; 95% confidence interval:
0.29–0.66). The results are summarised in Table 3 and show no
statistically significant association between dichotomised expres-
sion levels (T/N ratiop3.318 vs 43.318). The sensitivity to predict
minor histopathologic response was 20.8%, with a specificity of
100% (P¼0.15).
There was no significant association between dichotomised
mRNA levels for T/N ratios p1.0 vs 41 and histologic type
(P¼0.17), pT categories (P¼1), pN categories (P¼0.25) and
grading (P¼1) and T/N ratios p3.32 vs 43.32 and histologic type
(P¼0.63), pT categories (P¼0.0.63), pN categories (P¼1) and
grading (P¼0.65) by Fisher’s exact test.
Table 2 c-erbB-1 mRNA expression and regression (sensitivity and
specificity of response prediction)
Regression grading
c-erbB-1
a
Grades I/II
(MiHR
b)
Grades III/IV
(MaHR
c)
Total:
n (%)
p1: n (%) 11 (30.6%) 5 (13.9%) 16 (44.4%)
41: n (%) 13 (36.1%) 7 (19.4%) 20 (55.6%)
Total: n (%) 24 (66.7%) 12 (33.3%) 36 (100%)
aDichotomised c-erbB-1 mRNA levels.
bMinor histopathologic response.
cMajor
histopathologic response. Prediction of MiHR (c-erbB141): sensitivity 54.1%,
specificity: 65% w
2-analysis (Fisher’s exact test): P¼1.
Table 3 c-erbB-1 mRNA expression and regression (sensitivity and
specificity of response prediction for maximum cutoff)
Regression grading
c-erbB-1
a
Grades I/II
(MiHR
b)
Grades III/IV
(MaHR
c)
Total:
n (%)
p3.318: n (%) 19 (52.8%) 12 (33.3%) 31 (86.1%)
43.318: n (%) 5 (13.9%) + 5 (13.9%)
Total: n (%) 24 (66.7%) 12 (33.3%) 36 (100%)
aDichotomised c-erbB-1 mRNA levels.
bMinor histopathologic response.
cMajor
histopathologic response. Prediction of MiHR (c-erbB143.32): sensitivity 20.8%,
specificity: 100% w
2-analysis (Fisher’s exact test): P¼0.15.
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c-erbB-2 mRNA expression
The response frequencies for the 36 tumours analysed for c-erbB-2
expression were as follows: 12 out of 36 (33.3%) of the tumours
demonstrated major (grades III and IV) and 24 out of 33 (66.7%)
minor histopathologic response (grades I and II) to our
neoadjuvant treatment regimen.
Relative overexpression of c-erbB-2 mRNA with a T/N ratio
41.0 was detected in 10 out of 36 (27.8%) tumours, and normal to
low relative expression with a T/N ratio p1.0 in 26 out of 36
(72.2%), respectively. In addition, a cutoff value for relative c-
erbB-2 mRNA expression and maximum discrimination of minor
histopathologic response was calculated from ROC curves for a
relative c-erbB-2 mRNA expression level of 1.06 (area under the
curve: 0.62; 95% confidence interval: 0.42–0.81). This calculated
cutoff value, however, showed identical results when compared to
dichotomised expression levels at T/N ratios p1.0 vs 41 (Table 4).
There was no significant association between dichotomised
mRNA levels for T/N ratios p1.0 vs 41o rp1.06 vs 41.06 and
histologic types (P¼1.0), pT categories (P¼0.93), pN categories
(P¼0.21) and grading (P¼1).
Table 4 shows the association between major and minor
histopathologic response groups and dichotomised relative c-
erbB-2 expression levels for the whole study group (n¼36), Table 5
for patients with squamous cell histology (n¼23) and Table 6 for
adenocarcinomas (n¼13). The sensitivity for detection of a minor
histopathologic response was 41.6% for the whole group, 42.8% for
squamous cell cancers and 40% for adenocarcinomas with a
specificity of 100% in all the three groups. This association of
dichotomised c-erbB-2 mRNA levels and histopathologic response
was significant for the whole group of tumours (Po0.015) and the
subgroup of squamous cell cancers (Po0.048). Statistical analysis
was not possible for adenocarcinomas due to small (n¼13) patient
numbers.
In summary, quantitative c-erbB2 mRNA expression testing
unequivocally identified 10 out of 36 (28%) patients, whose
tumours did not respond well to the delivered neoadjuvant
radiochemotherapy (Figure 1).
DISCUSSION
A significant association between quantitative c-erbB-2 but not c-
erbB-1 mRNA expression levels in oesophageal cancers and minor
histopathologic response to CDDP/5-FU-based neoadjuvant radio-
chemotherapy could be demonstrated. In fact, quantitative c-erbB-
2 mRNA expression testing by real-time RT–PCR unequivocally
identified 10 out of 36 (28%) patients, whose tumours did not
exhibit (specificity 100%) a major histopathologic response to the
applied preoperative treatment.
Several in vitro studies demonstrated that EGF and EGFR
expression enhanced the sensitivity to various anticancer agents
(Dixit et al, 1997; Nouri et al, 2000) and radiotherapy (Kwok and
Sutherland, 1989; Bonner et al, 2002). Kroning et al (1995) showed
the improvement of drug sensitivity including CDDP and 5-
fluorouracil by EGF in various cell lines. Furthermore, they
described that enhancement of drug sensitivity depended on the
Table 4 c-erbB-2 mRNA expression and regression (sensitivity and
specificity of response prediction)
Regression grading
c-erbB-2
a
Grades I/II
(MiHR
b)
Grades III/IV
(MaHR
c)
Total:
n (%)
p1o rp1.06: n (%)
d 14 (38.9%) 12 (33.3%) 26 (72.2%)
41o r41.06: n (%)
d 10 (27.8%) + 10 (27.8%)
Total: n (%) 24 (66.7%%) 12 (33.3%) 36 (100%)
aDichotomised c-erbB-2 mRNA levels.
bMinor histopathologic response.
cMajor
histopathologic response.
dAll values remain identical if maximum cutoff at 1.06 was
chosen from ROC curves. w
2-analysis (Fisher’s exact test): P¼0.015. Prediction of
MiHR (c-erbB2 41): sensitivity 41.6%, specificity: 100%.
Table 5 c-erbB-2 mRNA expression and regression in SCC
a (sensitivity
and specificity of response prediction)
Regression grading
c-erbB-2
b
Grades I/II
(MiHR
c)
Grades III/IV
(MaHR
d)
Total:
n (%)
p1o rp1.06
e: n (%) 8 (34.8%) 9 (39.1%) 17 (73.9%)
41o r41.06
e: n (%) 6 (26.1%) + 6 (26.1%)
Total: n (%) 14 (60.9%) 9 (39.1%) 23 (100%)
aSquamous cell cancer.
bDichotomised c-erbB-2 mRNA levels.
cMinor histopatho-
logic response.
dMajor histopathologic response.
eAll values remain identical if
maximum cutoff at 1.06 was chosen from ROC curves. w
2-analysis (Fisher’s exact
test): P¼0.048. Prediction of MiHR (c-erbB-2 41): sensitivity 42.8%, specificity:
100%.
Table 6 c-erbB-2 mRNA expression and regression in AC
a (sensitivity
and specificity of response prediction)
Regression grading
c-erbB-2
b
Grades I/II
(MiHR
c)
Grades III/IV
(MaHR
d)
Total:
n (%)
p1o rp1.06
e: n (%) 6 (46.2%) 3 (23.1%) 9 (69.2%)
41o r41.06
e: n (%) 4 (30.8%) + 4 (30.8%)
Total: n (%) 10 (76.9%) 3 (23.1%) 13 (100%)
aAdenocarcinoma.
bDichotomised c-erbB-2 mRNA levels.
cMinor histopathologic
response.
dMajor histopathologic response.
eAll values remain identical if maximum
cutoff at 1.06 was chosen from ROC curves. w
2-analysis (Fisher’s exact test): not
possible (three cells with expected frequencies o5). Prediction of MiHR (c-erbB-2
41): sensitivity 40%, specificity: 100%.
Figure 1 Scattergram showing relative c-erbB-2 mRNA expression
levels (T/N: ratio of tumour to normal tissue) in relation to minor and major
histopathologic response in resected specimens. C-erbB-2 expression
levels 41 are exclusively present in the group of minor histopathologic
response (sensitivity: 41.6%, specificity: 100%).
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of EGFR signalling had an inhibitory effect on the repair of CDDP-
damaged DNA. Despite positive in vitro data, clinical trials failed
to demonstrate the relation between EGFR expression and
response to chemotherapy with CDDP-containing regimens (Goff
et al, 1998; Baekelandt et al, 1999). There is a possibility for a more
complex in vivo reaction process between EGFR, cytotoxic agents
and radiation-induced DNA damage.
Concerning our negative clinical results, it is necessary to point
out that EGFR mRNA expression levels were examined in
pretreatment biopsies only, so that we cannot rule out that
induction of EGFR expression and signalling during radio-
chemotherapy as shown in vitro could contribute to progressive
loss of chemo- and radiation sensitivity during the course of
radiochemotherapy. In addition, our data also do not advocate
against the potential benefit of an EGFR-targeted therapy
(Anderson and Jankowski, 2003; Gee and Nicholson, 2003).
Nevertheless, EGFR mRNA expression testing in pretreatment
biopsies did not significantly contribute to the identification of
patients with major or minor response to our radiochemotherapy
protocol.
Contrary to the c-erbB-1 expression data, increased relative
c-erbB-2 mRNA levels prior to the beginning of preoperative
radiochemotherapy proved to be a statistically significant factor in
predicting minor histopathologic response (Po0.01) in our
clinical setting.
It is known from previous studies that c-erbB-2 overexpression
can induce chemoresistance against various cytotoxic agents
(Allred et al, 1992; Benz et al, 1993; Miles et al, 1999; Menard
et al, 2001) and several groups demonstrated that anti-c-erbB2
(p185)-specific antibodies enhanced the cytotoxic sensitivity in
high p185 protein-expressing cell lines (Hancock et al, 1991;
Pietras et al, 1994; Tsai et al, 1995). Tsai et al (1996) concluded
from in vitro experiments using non-small cell lung cancer cell
lines that high levels of p185 can promote DNA repair after
exposure to cytotoxic agents.
In clinical studies, it has been shown that overexpression of
c-erbB-2 protein induced chemoresistance in breast and ovarian
cancers (Muss et al, 1994; Meden et al, 1998; Jukkola et al, 2001).
Other studies, however, failed to demonstrate a relation between
c-erbB-2 expression and chemotherapy response in breast, ovarian
or squamous cell head and neck cancers (Makar et al, 1994; Rozan
et al, 1998; Giatromanolaki et al, 2000).
Clinical response evaluation after neoadjuvant therapy in solid
tumours is highly inaccurate, as shown for oesophageal cancer
(Adelstein et al, 1997). In contrast, histopathologic evaluation
results in an objective analysis of remission with prognostic
importance, as convincingly demonstrated for non-small cell lung
cancer (Junker et al, 1997; Thomas et al, 1999). PET imaging might
further improve clinical response evaluation, which, however, is
currently still under investigation (Bruecher et al, 2001; Downey
et al, 2003).
We therefore applied histopathologic criteria instead of
inaccurate clinical restaging modalities for objective response
evaluation in neoadjuvant-treated oesophageal cancers and
identified a significant association between minor histopathologic
response and dichotomised relative c-erbB-2 mRNA expression
levels (Po0.01).
The sensitivity for the whole group of oesophageal cancers is
41.6%. More important, however, is the specificity of 100%, which
would allow the unequivocal identification of a subset of 28% of
patients with minor responses prior to treatment. Although
median follow-up is too short to allow a definitive evaluation
between the association of c-erbB-2 expression levels and survival,
it has been convincingly demonstrated in the past that only
patients with major histopathologic responses benefit from this
type of treatment independent of the applied protocol (Walsh et al,
1996; Urba et al, 2001; MRC Esophageal Study Group, 2002).
The present, still early, results of this ongoing study are
promising, and it appears that we could expect to identify
approximately one-fourth of patients who in principal fulfil the
criteria for neoadjuvant treatment for locally advanced oesopha-
geal cancer, who will, however, not benefit from our treatment
protocol. This might prevent a substantial number of our patients
from expensive, noneffective and potentially harmful therapies,
and could lead to a more individualised type of combined
multimodality treatment in the near future. Quantitative real-time
RT–PCR is a very efficient and fast technology that could easily be
incorporated in a clinical setting, since results can be obtained
within 1 or 2 days. A very promising approach could also be the
application of specific anti-p185 antibodies or tyrosine kinase
inhibitors in addition to radiochemotherapy in patients over-
expressing c-erbB-2.
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